文献速递肺栓塞与肺血管病

轻度肺实质病变和/或低弥散能力影响特发性肺动脉高压患者的生存和治疗反应

Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension.
PubMed 文献 · Eur Respir J · 2020-06-04

基于ASPIRE注册研究2001-2019年确诊的IPAH患者,按CT和肺功能分为无肺病组(IPAHno-LD,n=303)和轻度肺病组(IPAHmild-LD,n=190)。IPAHno-LD组1年和5年生存率分别为95%和70%,显著优于IPAHmild-LD组的78%和22%(p<0.0001)。IPAHno-LD组治疗后运动能力和生活质量改善(均p<0.0001),而IPAHmild-LD组未改善。

要点

  • 即使轻度肺实质病变也显著降低IPAH患者生存率。
  • IPAHmild-LD患者治疗后运动能力和生活质量未改善。
  • IPAHno-LD中DLCO<45%者生存更差但治疗可改善运动能力。

核心结论

  • 符合当前IPAH诊断标准的患者中,即使存在轻度肺实质病变也显著影响结局。
  • 该表型可通过肺功能检查和临床CT报告识别。
  • IPAH无肺病且DLCO严重降低者可能代表进一步不同的表型。

研究设计与样本

  • 基于ASPIRE注册研究,纳入2001-2019年确诊的IPAH患者。
  • 使用预设的CT影像和肺量计标准,分为IPAHno-LD(n=303)和IPAHmild-LD(n=190)。

主要发现

  • IPAHno-LD组1年和5年生存率分别为95%和70%,IPAHmild-LD组分别为78%和22%(p<0.0001)。
  • 在IPAHno-LD和IPAHmild-LD合并组中,较高死亡率的独立预测因素包括年龄增加、较低的DLCO、较低的运动能力和IPAHmild-LD诊断(均p<0.05)。
  • IPAHno-LD组治疗后运动能力和生活质量改善(均p<0.0001),IPAHmild-LD组未改善。
  • 部分IPAHno-LD患者DLCO<45%,其生存率低于DLCO≥45%者,但治疗后运动能力改善。

临床怎么用

  • 对IPAH患者应结合肺功能(DLCO)和CT报告评估是否合并轻度肺实质病变。
  • 合并轻度肺病者预后较差,治疗反应可能不佳,需更密切随访。
  • IPAH无肺病但DLCO<45%者应识别为可能的不同表型。

局限性

  • 数据来自单中心注册研究,需随机对照试验验证这些表型的靶向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There are limited published data defining survival and treatment response in patients with mild lung disease and/or reduced gas transfer who fulfil diagnostic criteria for idiopathic pulmonary arterial hypertension (IPAH).Patients diagnosed with IPAH between 2001 and 2019 were identified in the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Centre) registry. Using prespecified criteria based on computed tomography (CT) imaging and spirometry, patients with a diagnosis of IPAH and no lung disease were termed IPAHno-LD (n=303), and those with minor/mild emphysema or fibrosis were described as IPAHmild-LD (n=190).Survival was significantly better in IPAHno-LD than in IPAHmild-LD (1- and 5-year survival 95% and 70% versus 78% and 22%, respectively; p<0.0001). In the combined group of IPAHno-LD and IPAHmild-LD, independent predictors of higher mortality were increasing age, lower diffusing capacity of the lung for carbon monoxide (D LCO), lower exercise capacity and a diagnosis of IPAHmild-LD (all p<0.05). Exercise capacity and quality of life improved (both p<0.0001) following treatment in patients with IPAHno-LD, but not IPAHmild-LD A proportion of patients with IPAHno-LD had a D LCO <45%; these patients had poorer survival than patients with D LCO ≥45%, although they demonstrated improved exercise capacity following treatment.The presence of even mild parenchymal lung disease in patients who would be classified as IPAH according to current recommendations has a significant adverse effect on outcomes. This phenotype can be identified using lung function testing and clinical CT reports. Patients with IPAH, no lung disease and severely reduced D LCO may represent a further distinct phenotype. These data suggest that randomised controlled trials of targeted therapies in patients with these phenotypes are required.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Lewis RA, Thompson AAR, Billings CG, et al. Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Eur Respir J. 2020. PMID: 32108045. doi:10.1183/13993003.00041-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。